Drugs / Nelipepimut-S
Trials 4 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 23 trials | ||||||
| Phase 2 | NCT02636582 | Jun 2016 → Jul 2019 | ductal breast carcinoma in situ | National Cancer Institute (NCI) | Completed | No outcome recorded |
| Phase 2 | NCT02297698 | Oct 2014 → Dec 2021 | breast cancer | Cancer Insight, LLC | Completed | No outcome recorded |
| Phase 2 | NCT01570036 | May 2013 → Sep 2018 | breast cancer | George E. Peoples | Completed | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT01479244 | Nov 2011 → Sep 2016 | breast carcinoma by gene expression profile | Galena Biopharma, Inc. | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | nelipepimut-S | “Efficacy and Safety Analysis of Nelipepimut-S Vaccine to Prevent Breast Cancer Recurrence: A Randomized, Multicenter, Phase III Clinical Trial.” PMID 31036542 ↗ Apr 20193“Patients received trastuzumab for 1 year and were randomized to placebo (GM-CSF, control) or nelipepimut-S (NPS) with GM-CSF.” PMID 32071118 ↗ Feb 2020 “Nelipepimut-S is a CD8-eliciting peptide vaccine” NCT02297698 ↗ |
| Known as | NP-S | “In phase I/II studies, nelipepimut-S (NP-S) plus GM-CSF vaccine was well tolerated and effectively raised HER2-specific immunity in patients with breast cancer.” PMID 31036542 ↗ Apr 20191“Patients received trastuzumab for 1 year and were randomized to placebo (GM-CSF, control) or nelipepimut-S (NPS) with GM-CSF.” PMID 32071118 ↗ Feb 2020 |
| Modality | Vaccine | “Nelipepimut-S is a CD8-eliciting peptide vaccine” NCT02297698 ↗ |
| Route | Other | “nelipepimut-S (1000 mcg) and GM-CSF (250 mcg) administered intradermally every three weeks” NCT02297698 ↗ |